Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT01662609|
Recruitment Status : Active, not recruiting
First Posted : August 10, 2012
Last Update Posted : July 12, 2018
|Condition or disease||Intervention/treatment|
|Pancreatic Cancer||Procedure: Endoscopic Ultrasound (EUS)|
|Study Type :||Observational|
|Actual Enrollment :||90 participants|
|Official Title:||Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer at Moffitt Cancer Center and Lehigh Valley Hospital|
|Actual Study Start Date :||June 1, 2007|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||June 2020|
Endoscopic Ultrasound (EUS) Participants
High-risk for Pancreatic Cancer: Patients with 2 or more relatives with pancreatic cancer and a first degree relationship with at least one of the relatives with pancreatic cancer.
Procedure: Endoscopic Ultrasound (EUS)
Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
Other Name: ultrasound scope
- Number of Abnormalities Detected by EUS [ Time Frame: Average of 5 years ]To determine whether targeted screening of these high-risk individuals using Endoscopic Ultrasound (EUS) at regular intervals can detect precancerous pancreas changes or early stage asymptomatic pancreatic cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01662609
|United States, Florida|
|H. Lee Moffitt Cancer Center and Research Institute|
|Tampa, Florida, United States, 33612|
|United States, Pennsylvania|
|Lehigh Valley Health Network|
|Allentown, Pennsylvania, United States, 18105|
|Principal Investigator:||Jason Klapman, M.D.||H. Lee Moffitt Cancer Center and Research Institute|